<DOC>
	<DOCNO>NCT00003151</DOCNO>
	<brief_summary>RATIONALE : Antibiotics may stop growth Helicobacter pylorus may associate gastric lymphoma . PURPOSE : Phase II trial study effectiveness antibiotic therapy treat patient low grade gastric lymphoma previously treat .</brief_summary>
	<brief_title>Antibiotic Therapy Treating Patients With Low Grade Gastric Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate eradication Helicobacter pylorus use omeprazole , colloidal bismuth subcitrate , tetracycline , metronidazole patient low grade gastric lymphoma . II . Determine macroscopic/endoscopic microscopic healing/remission rate eradication Helicobacter pylorus patient population . III . Determine natural history low grade gastric lymphoma eradication Helicobacter pylorus . OUTLINE : This nonrandomized , open label , multicenter study . Patients receive oral omeprazole bid day 1-10 , oral bismuth subcitrate oral tetracycline qid day 4-10 , oral metronidazole tid day 4-10 . Patients evaluate 8 week . Patients experience complete remission H. pylori negative proceed follow . Patients complete remission change H. pylorus positive proceed second course therapy previous schedule omeprazole bid , amoxicillin qid , clarithromycin tid 14 day . Patients experience change H. pylorus negative follow 6 9 month restaged . Patients follow 6 , 9 , 12 , 18 , 24 month , annually thereafter . PROJECTED ACCRUAL : Approximately 60-96 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth tripotassium dicitrate</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , previously untreated , low grade gastric lymphoma Clinical stage I II1 No bulky disease No high grade component ( grade 5 4 , monoclonality proven , allow ) Documented presence/absence H. pylori infection Measurable and/or evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant lactate Fertile patient must use effective contraception No prior concurrent malignancy unless : At least 1 year remission Low risk recurrence No prior gastric malignancy No nonmalignant disease cause poor medical risk No allergy omeprazole PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy abdomen Surgery : No prior gastric surgery except simple closure perforate ulcer without wedge excision ulcer Other : No prior therapy gastric lymphoma At least 30 day since experimental therapy No concurrent experimental therapy At least 30 day since antibiotic activity H. pylorus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
</DOC>